ATR Earnings

ATR reported its earnings on 2026-02-05, showcasing a revenue of 0.00 against an estimate of 897.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 1.24 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ATR's earnings announcement on 2026-02-05, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, ATR's stock price tends to shift by an average of -0.43% in the 10 days leading up to earnings and +1.34% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ATR’s annual revenue to reach 880.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.32% and EPS estimates Revise Downward by -2.96% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ATR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.32%, while EPS estimates moved Revise Downward by -2.96% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ATR's stock price typically moves by -0.43% in the 10 days before its earnings and +1.34% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 880.00M.

The earnings call summary shows mixed results: strong performance in the Pharma segment with positive growth expectations, but challenges in Beauty and Closures segments. The Q&A reveals uncertainties, particularly in emergency medicine and litigation costs, causing concern. Although there are positive long-term growth prospects, the lack of specific guidance and declining margins in some segments temper optimism. Given these factors, the overall sentiment is neutral, with no strong catalysts for significant stock price movement in either direction over the next two weeks.